Abstracts tagged "Histone Modification"

Abstract Number: 2731 • 2013 ACR/ARHP Annual Meeting
An Acetyl-Histone Mimetic Blocks Proinflammatory Activation Of Rheumatoid Arthritis Fibroblast-Like Synoviocytes
P. A. Kabala¹, A.M. Grabiec¹, C. Angiolilli¹, Nicholas Smithers², Jason Witherington³, Paul Peter Tak⁴, Rabinder Prinjha³ and Kris A. Reedquist⁵, ¹Department of Experimental Immunology, Department of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Immuno Inflammation, GlaxoSmithKline, Stevenage, United Kingdom, ³GlaxoSmithKline, Stevenage, United Kingdom, ⁴Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands, ⁵Department of Experimental Immunology and Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Genetic backgrounds and environmental factors do not completely explain the etiology of disease and predisposition to rheumatoid arthritis (RA), and increasing attention has turned…
Abstract Number: 2424 • 2013 ACR/ARHP Annual Meeting
Investigation Of The Role Of Histone Deacetylases In Rheumatoid Arthritis Synovial Fibroblasts
Sarah Hawtree¹, Munitta Muthana¹, Sarah Aynsley¹, J. Mark Wilkinson² and Anthony G. Wilson³, ¹Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ²Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom, ³Infection & Immunity, University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects synovial joints. A key characteristic of RA is hyperplasia of fibroblast-like synoviocytes (FLS).…
Abstract Number: 2399 • 2013 ACR/ARHP Annual Meeting
Altered Histone Methylation Is Associated With IL-6 Dependent Matrix Metalloproteinases Gene Transcriptional Activation In Rheumatoid Arthritis Synovial Fibroblasts
Yasuto Araki^1,2, Takuma Tsuzuki Wada^1,2, Kojiro Sato¹, Kazuhiro Yokota¹, Fumihiko Miyoshi¹, Yu F. Asanuma³, Yuji Akiyama¹ and Toshihide Mimura^1,2, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease which causes progressive joint destruction. In spite of the modern medications including biologic reagents, it…
Abstract Number: 2216 • 2013 ACR/ARHP Annual Meeting
Tubastatin A, a Selective Histone Deacetylase-6 Inhibitor, Suppresses Synovial Inflammation and Joint Destruction In a Collagen Antibody-Induced Arthritis Mouse Model
Joong Kyong Ahn¹, Jaejoon Lee², Hyemin Jeong², Jiwon Hwang², Seulkee Lee², Ji Young Chai³, Inyoung Kim^2,4, Eun Chung Hong⁵, Eun-Kyung Bae⁵, Hoon-Suk Cha² and Eun-Mi Koh², ¹Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Division of Rheumatology, Jesang Hospital, Seongnam-si Gyeonggi-do, South Korea, ⁴MD, Seoul, South Korea, ⁵Samsung Biomedical Research Institute, Seoul, South Korea
Background/Purpose: Histone deacetylases (HDAC) play a key role in regulating gene expression by deacetylasing histones, and HDAC inhibitors induce various cellular effects, including apoptosis, cell…
Abstract Number: 1625 • 2013 ACR/ARHP Annual Meeting
Prolactin-Induced Interferon Regulatory Factor 1 Activation and Histone H4 Hyperacetylation In Monomac-6 Cells Correlating With Changes Seen In Monocytes From Systemic Lupus Erythematosus Patients
Yiu Tak Leung¹, Lihua Shi², Kelly Maurer², Li Song², Michelle Petri³ and Kate Sullivan⁴, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Epigenetic changes have been described in systemic lupus erythematosus (SLE) and offer a potential explanation for the chronicity of disease and missing heritability. Therapies…
Abstract Number: 1380 • 2013 ACR/ARHP Annual Meeting
Histone Modifications In The Interluekin-6 Gene Promoter Region Of Rheumatoid Arthritis Synovial Fibroblasts
Takuma Tsuzuki Wada^1,2, Yasuto Araki^1,2, Kazuhiro Yokota¹, Fumihiko Miyoshi¹, Kojiro Sato¹ and Toshihide Mimura^1,2, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: , Rheumatoid arthritis (RA) is a disease of unknown origin, which develops continuous inflammation and progressive joint destruction resulting from an autoimmune response mainly…
Abstract Number: L8 • 2013 ACR/ARHP Annual Meeting
Overexpression of Set1 at the Promoter Contributes to cAMP Response Element Modulator Alpha Overexpression in Systemic Lupus Erythematosus
Qing Zhang¹, Huilin Zhang², Hai Long¹, Jieyue Liao³, Ming Zhao¹, Xiangning Qiu¹ and Qianjin Lu¹, ¹Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, ²Nursing Department, Second Xiangya Hospital, Central South University, Changsha, China, ³Department of Dermatology, Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: In recent years, accumulating evidence has demonstrated that increased cAMP response element modulator α (CREMα) which contributes to IL-2 reduction and IL-17A overproduction in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].